Skip to main content
Log in

Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare (occurring in approximately 2 to 3 people/million population/year in Europe and the US), life-threatening, intolerance reaction of the skin. It is most often caused by drugs (most commonly sulfonamides, nonsteroidal anti-inflammatory drugs, antimalarials, anticonvulsants, and allopurinol).

SJS/TEN is characterized by a macular exanthema (‘atypical targets’) which focusses on the face, neck, and the central trunk regions. Lesions show rapid confluence, a positive Nikolsky’s sign, and quickly result in widespread detachment of the epidermis and erosions. Mucosal, conjunctival, and anogenital mucous membranes are prominently involved. Histopathology shows satellite cell necrosis in the early stages progressing to full thickness necrosis of the epidermis, contrasting with rather inconspicuous inflammatory infiltrates of the dermis. Damage to the skin is thought to be mediated by cytotoxic T lymphocytes and mononuclear cells which induce apoptosis in keratinocytes expressing drug-derived antigens at their surfaces.

No guidelines for the treatment of SJS/TEN exist since no controlled clinical trials have ever been performed. The controversy over whether systemic corticosteroids should be used to curtail progression is still unresolved; while many authors agree that corticosteroids do in fact suppress progression, it is obvious that they also greatly enhance the risk of infection, the complication which most frequently leads to a fatal outcome. It appears reasonable to only administer corticosteroids in the phase of progression and to withdraw them as soon as possible, and to add antibacterials for prophylaxis. Recently, in a small series of patients, intravenous immunoglobulins were presumed to be effective by the blockade of lytic Fas ligand-mediated apoptosis in SJS/TEN. However, these results have to be confirmed by large clinical trials. Supportive treatment and monitoring of vital functions is of utmost importance in SJS/TEN, and out-patient treatment is unacceptable. Recovery is usually slow, depending on the extent and severity and the presence of complications, and may take 3 to 6 weeks. Skin lesions heal without scars as a rule, but scarring of mucosal sites is a frequent late complication, potentially leading to blindness, obliteration of the fornices and anogenital strictures.

There is no reliable laboratory test to determine the offending drug; diagnosis rests on the patient’s history and the empirical risk of drugs to elicit skin SJS/TEN. Provocation tests are not indicated since re-exposure is likely to elicit a new episode of SJS/TEN of increased severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Table II

Similar content being viewed by others

References

  1. Bastuji-Garin S., Rzany B., Stern R.S., et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129 (1): 92–96

    Article  PubMed  CAS  Google Scholar 

  2. Roujeau J.C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102 (6): 28S–30S

    Article  PubMed  CAS  Google Scholar 

  3. Fritsch P.O., Ruiz-Maldonado R. Erythema nultiforme. In: Freedberg I.M., Eisen A.Z., Wolff K., et al., editors. Fitzpatrick’s Dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 636–644

    Google Scholar 

  4. Fritsch P.O., Ruiz-Maldonado R. Stevens-Johnson syndrome — toxic epidermal necrolysis. In: Freedberg I.M., Eisen A.Z., Wolff K., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 644–654

    Google Scholar 

  5. Assier H., Bastuji-Garin S., Revuz J., et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131 (5): 539–543

    Article  PubMed  CAS  Google Scholar 

  6. Rzany B., Mockenhaupt M., Baur S., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49 (7): 769–773

    Article  PubMed  CAS  Google Scholar 

  7. Naldi L., Locati F., Marchesi L., et al. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126 (8): 1103–1104

    Article  PubMed  CAS  Google Scholar 

  8. Roujeau J.C., Guillaume J.C., Fabre J.P., et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol 1990; 126 (1): 37–42

    Article  PubMed  CAS  Google Scholar 

  9. Schöpf E., Stuhmer A., Rzany B., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991; 127 (6): 839–842

    Article  PubMed  Google Scholar 

  10. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13 (4): 623–635

    Article  PubMed  CAS  Google Scholar 

  11. Roujeau J.C., Huynh T.N., Bracq C., et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123 (9): 1171–1173

    Article  PubMed  CAS  Google Scholar 

  12. Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333 (24): 1600–1607

    Article  PubMed  CAS  Google Scholar 

  13. Lebargy F., Wolkenstein P., Gisselbrecht M., et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intens Care Med 1997; 23 (12): 1237–1244

    Article  CAS  Google Scholar 

  14. McIvor R.A., Zaidi J., Peters W.J., et al. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996; 17 (3): 237–240

    Article  PubMed  CAS  Google Scholar 

  15. Michel P., Joly P., Ducrotte P., et al. Ileal involvement in toxic epidermal necrolysis (Lyell syndrome). Dig Dis Sci 1993; 38 (10): 1938–1941

    Article  PubMed  CAS  Google Scholar 

  16. Blum L., Chosidow O., Rostoker G., et al. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol 1996; 34 (6): 1088–1090

    Article  PubMed  CAS  Google Scholar 

  17. Wilson E.E., Malinak L.R. Vulvovaginal sequelae of Stevens-Johnson syndrome and their management. Obstet Gynecol 1988; 71 (3 Pt 2): 478–480

    PubMed  CAS  Google Scholar 

  18. Meneux E., Paniel B.J., Pouget F., et al. Vulvovaginal sequelae in toxic epidermal necrolysis. J Reprod Med 1997; 42 (3): 153–156

    PubMed  CAS  Google Scholar 

  19. Paquet P., Pierard G.E. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997; 19 (2): 127–132

    Article  PubMed  CAS  Google Scholar 

  20. Resnick S.D., Elias P.M. Staphylococcal Scalded Skin Syndrome. In: Freedberg I.M., Eisen A.Z., Wolff K., et al., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 2207–2211

    Google Scholar 

  21. Peck G.L., Herzig G.P., Elias P.M. Toxic epidermal necrolysis in a patient with graft-vs-host reaction. Arch Dermatol 1972; 105 (4): 561–569

    Article  PubMed  CAS  Google Scholar 

  22. Villada G., Roujeau J.C., Cordonnier C., et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 1990; 23 (5 Pt 1): 870–875

    Article  PubMed  CAS  Google Scholar 

  23. Stone N., Sheerin S., Burge S. Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol 1999; 24 (4): 260–262

    Article  PubMed  CAS  Google Scholar 

  24. Ford M.J., Smith K.L., Croker B.P., et al. Large granular lymphocytes within the epidermis of erythema multiforme lesions. J Am Acad Dermatol 1992; 27 (3): 460–462

    Article  PubMed  CAS  Google Scholar 

  25. Correia O., Delgado L., Ramos J.P., et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129 (4): 466–468

    Article  PubMed  CAS  Google Scholar 

  26. Villada G., Roujeau J.C., Clerici T., et al. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases [see comments]. Arch Dermatol 1992; 128 (1): 50–53

    Article  PubMed  CAS  Google Scholar 

  27. Paquet P., Nikkels A., Arrese J.E., et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis [see comments]. Arch Dermatol 1994; 130 (5): 605–608

    Article  PubMed  CAS  Google Scholar 

  28. Redondo P., Vicente J., Espana A., et al. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol 1996; 135 (6): 999–1002

    Article  PubMed  CAS  Google Scholar 

  29. Fleischer Jr A.B., Rosenthal D.I., Bernard S.A., et al. Skin reactions to radiotherapy — a spectrum resembling erythema multiforme: case report and review of the literature. Cutis 1992; 49 (1): 35–39

    PubMed  Google Scholar 

  30. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282 (5388): 490–493

    Article  PubMed  CAS  Google Scholar 

  31. Mauri-Hellweg D., Bettens F., Mauri D., et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155 (1): 462–472

    PubMed  CAS  Google Scholar 

  32. Wolkenstein P., Charue D., Laurent P., et al. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995; 131 (5): 544–551

    Article  PubMed  CAS  Google Scholar 

  33. Wolkenstein P., Carriere V., Charue D., et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5 (4): 255–258

    Article  PubMed  CAS  Google Scholar 

  34. Shear N.H., Spielberg S.P., Grant D.M., et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105 (2): 179–184

    PubMed  CAS  Google Scholar 

  35. Guillaume J.C., Roujeau J.C., Revuz J., et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell’s syndrome). Arch Dermatol 1987; 123 (9): 1166–1170

    Article  PubMed  CAS  Google Scholar 

  36. Stern R.S., Chan H.L. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989; 21 (2 Pt 1): 317–322

    Article  PubMed  CAS  Google Scholar 

  37. Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353 (9171): 2190–2194

    Article  PubMed  CAS  Google Scholar 

  38. Pasricha J.S., Khaitan B.K., Shantharaman R., et al. Toxic epidermal necrolysis. Int J Dermatol 1996; 35 (7): 523–527

    Article  PubMed  CAS  Google Scholar 

  39. Cheriyan S., Patterson R., Greenberger P.A., et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 1995; 16 (4): 151–155

    Article  PubMed  CAS  Google Scholar 

  40. Heng M.C. Drug-induced toxic epidermal necrolysis. Br J Dermatol 1985; 113 (5): 597–600

    Article  PubMed  CAS  Google Scholar 

  41. Kakourou T., Klontza D., Soteropoulou F., et al. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr 1997; 156 (2): 90–93

    Article  PubMed  CAS  Google Scholar 

  42. Stables G.I., Lever R.S. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993; 128 (3): 357

    Article  PubMed  CAS  Google Scholar 

  43. Parsons J.M. Toxic epidermal necrolysis. Int J Dermatol 1992; 31 (11): 749–768

    Article  PubMed  CAS  Google Scholar 

  44. Revuz J., Penso D., Roujeau J.C., et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123 (9): 1160–1165

    Article  PubMed  CAS  Google Scholar 

  45. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331 (19): 1272–1285

    Article  PubMed  CAS  Google Scholar 

  46. Halebian P.H., Corder V.J., Madden M.R., et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204 (5): 503–512

    Article  PubMed  CAS  Google Scholar 

  47. Roujeau J.C. Drug-induced toxic epidermal necrolysis. II. Current aspects. Clin Dermatol 1993; 11 (4): 493–500

    Article  PubMed  CAS  Google Scholar 

  48. Rzany B., Schmitt H., Schöpf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991; 71 (2): 171–172

    PubMed  CAS  Google Scholar 

  49. Guibal F., Bastuji-Garin S., Chosidow O., et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995; 131 (6): 669–672

    Article  PubMed  CAS  Google Scholar 

  50. Egan C.A., Grant W.J., Morris S.E., et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40 (3): 458–461

    Article  PubMed  CAS  Google Scholar 

  51. Kamanabroo D., Schmitz-Landgraf W., Czarnetzki B.M. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121 (12): 1548–1549

    Article  PubMed  CAS  Google Scholar 

  52. Sakellariou G., Koukoudis P., Karpouzas J., et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 1991; 14 (10): 634–638

    PubMed  CAS  Google Scholar 

  53. Chaidemenos G.C., Chrysomallis F., Sombolos K., et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997; 36 (3): 218–221

    Article  PubMed  CAS  Google Scholar 

  54. Frangogiannis N.G., Boridy I., Mazhar M., et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996; 89 (10): 1001–1003

    Article  PubMed  CAS  Google Scholar 

  55. Heng M.C., Allen S.G. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects [see comments]. J Am Acad Dermatol 1991; 25 (5 Pt 1): 778–786

    Article  PubMed  CAS  Google Scholar 

  56. Assier-Bonnet H., Aractingi S., Cadranel J., et al. Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. Br J Dermatol 1996; 135 (5): 864–866

    Article  PubMed  CAS  Google Scholar 

  57. Jarrett P., Rademaker M., Havill J., et al. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 1997; 22 (3): 146–147

    Article  PubMed  CAS  Google Scholar 

  58. Sullivan J.R., Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996; 37 (4): 208–212

    Article  PubMed  CAS  Google Scholar 

  59. Zaki I., Patel S., Reed R., et al. Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin. Br J Dermatol 1995; 133 (2): 337–338

    Article  PubMed  CAS  Google Scholar 

  60. Hewitt J., Ormerod A.D. Toxic epidermal necrolysis treated with cyclosporin. Clin Exp Dermatol 1992; 17 (4): 264–265

    Article  PubMed  CAS  Google Scholar 

  61. Renfro L., Grant-Kels J.M., Daman L.A. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989; 28 (7): 441–444

    Article  PubMed  CAS  Google Scholar 

  62. Paquet P., Pierard G.E. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999; 198 (2): 198–202

    Article  PubMed  CAS  Google Scholar 

  63. Redondo P., de Felipe I., de la Pena A., et al. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997; 136 (4): 645–646

    Article  PubMed  CAS  Google Scholar 

  64. Paquet P., Pierard G.E. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med 1998; 1 (2): 459–462

    PubMed  CAS  Google Scholar 

  65. Wolkenstein P., Latarjet J., Roujeau J.C., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352 (9140): 1586–1589

    Article  PubMed  CAS  Google Scholar 

  66. Klausner J.D., Kaplan G., Haslett P.A. Thalidomide in toxic epidermal necrolysis. Lancet 1999; 353 (9149): 324

    Article  PubMed  CAS  Google Scholar 

  67. Levy R. Thalidomide in toxic epidermal necrolysis. Lancet 1999; 353 (9149): 324

    Article  PubMed  CAS  Google Scholar 

  68. Revuz J., Roujeau J.C., Guillaume J.C., et al. Treatment of toxic epidermal necrolysis. Creteil’s experience. Arch Dermatol 1987; 123 (9): 1156–1158

    Article  PubMed  CAS  Google Scholar 

  69. Birchall N., Langdon R., Cuono C., et al. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol 1987; 16 (2 Pt 1): 368–372

    Article  PubMed  CAS  Google Scholar 

  70. Marvin J.A., Heimbach D.M., Engrav L.H., et al. Improved treatment of the Stevens-Johnson syndrome. Arch Surg 1984; 119 (5): 601–605

    Article  PubMed  CAS  Google Scholar 

  71. Bradley T., Brown R.E., Kucan J.O., et al. Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg 1995; 35 (2): 124–132

    Article  PubMed  CAS  Google Scholar 

  72. Belfort Jr R., de Smet M., Whitcup S.M., et al. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS. Cornea 1991; 10 (6): 536–538

    Article  PubMed  Google Scholar 

  73. Lehman S.S. Long-term ocular complication of Stevens-Johnson syndrome. Clin Pediatr (Phila) 1999; 38 (7): 425–427

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter O. Fritsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fritsch, P.O., Sidoroff, A. Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Am J Clin Dermatol 1, 349–360 (2000). https://doi.org/10.2165/00128071-200001060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200001060-00003

Keywords

Navigation